Neurocrine Biosciences Inc. (NBIX)

Profile

https://www.neurocrine.com

Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company headquartered in San Diego, California. The company specializes in discovering, developing, and commercializing medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its marketed portfolio addresses a range of conditions, including tardive dyskinesia and chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, adrenal insufficiency, endometriosis, and uterine fibroids. Key products include INGREZZA for movement disorders, ALKINDI and Efmody for adrenal-related conditions, Orilissa and Oriahnn for gynecologic disorders, and CRENESSITY for congenital adrenal hyperplasia. Following the acquisition of Soleno Therapeutics, Neurocrine Biosciences also offers VYKAT XR, a therapy targeting hyperphagia in Prader-Willi syndrome, expanding its presence in rare endocrine and metabolic diseases. The company serves patients and healthcare providers in the United States and internationally, playing a significant role in specialty pharmaceuticals for complex central nervous system and endocrine conditions. Founded in 1992, it operates today as a key player in the biopharmaceutical segment of the healthcare market.